These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24988935)

  • 1. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Jul; 15(8):e315-26. PubMed ID: 24988935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions in patients receiving tyrosine kinase inhibitors.
    Keller KL; Franquiz MJ; Duffy AP; Trovato JA
    J Oncol Pharm Pract; 2018 Mar; 24(2):110-115. PubMed ID: 27941080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of food-drug interactions with small-molecule kinase inhibitors.
    Veerman GDM; Hussaarts KGAM; Jansman FGA; Koolen SWL; van Leeuwen RWF; Mathijssen RHJ
    Lancet Oncol; 2020 May; 21(5):e265-e279. PubMed ID: 32359502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in bioavailability of small molecular tyrosine kinase inhibitors.
    Herbrink M; Nuijen B; Schellens JH; Beijnen JH
    Cancer Treat Rev; 2015 May; 41(5):412-22. PubMed ID: 25818541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: A clinical perspective.
    Cheng F; Wang H; Li W; Zhang Y
    Crit Rev Oncol Hematol; 2024 Mar; 195():104258. PubMed ID: 38307392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability of tyrosine kinase inhibitors: an added component of assessment.
    Abueg KD
    Clin J Oncol Nurs; 2014 Dec; 18(6):714-6. PubMed ID: 25427707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations.
    Teo YL; Ho HK; Chan A
    Br J Clin Pharmacol; 2015 Feb; 79(2):241-53. PubMed ID: 25125025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug interactions with solid tumour-targeted therapies.
    Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interactions with tyrosine-kinase inhibitors.
    Croes S; de Vries F
    Lancet Oncol; 2014 Sep; 15(10):e416. PubMed ID: 25186045
    [No Abstract]   [Full Text] [Related]  

  • 10. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy.
    Gay C; Toulet D; Le Corre P
    Hematol Oncol; 2017 Sep; 35(3):259-280. PubMed ID: 27925256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye.
    Yu G; Zheng QS; Wang DX; Zhou HH; Li GF
    Lancet Oncol; 2014 Oct; 15(11):e469-70. PubMed ID: 25281461
    [No Abstract]   [Full Text] [Related]  

  • 13. Drug interactions between tyrosine-kinase inhibitors and acid suppressive agents: more than meets the eye-Authors' reply.
    van Leeuwen RW; van Gelder T; Mathijssen RH; Jansman FG
    Lancet Oncol; 2014 Oct; 15(11):e470-1. PubMed ID: 25281462
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug interactions in oncology.
    Beijnen JH; Schellens JH
    Lancet Oncol; 2004 Aug; 5(8):489-96. PubMed ID: 15288238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring.
    Josephs DH; Fisher DS; Spicer J; Flanagan RJ
    Ther Drug Monit; 2013 Oct; 35(5):562-87. PubMed ID: 24052062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mecanisms of pharmacokinetic interactions involving oral anticancer agents].
    Levêque D; Duval C; Poulat C; Palas B; El Aatmani A; Dory A; Becker G; Gourieux B
    Bull Cancer; 2015 Jan; 102(1):65-72. PubMed ID: 25609481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia.
    Widmer N; Gotta V; Haouala A; Decosterd LA
    Leuk Res; 2010 Jun; 34(6):698-9. PubMed ID: 20074797
    [No Abstract]   [Full Text] [Related]  

  • 19. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.